VEGFA and neoplasm: In conclusion, the best regimen of sorafenib administration was administering sorafenib before the increased expression of VEGF, which could confer the greatest survival benefit by inhibiting VEGF-receptor expression via the bifunction of VEGF, and reducing tumor angiogenesis.